Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the ...

Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced it received a ...

Di condition of our lungs fit reveal many tins about our wider health. Luckily, you fit also get dem into beta shape.

Affinity Technologies' stock surged after a patent notice and Nasdaq compliance update but slipped in after-hours trading.

Affinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer ...

Affinity Technologies, Inc. ( (BIAF) ) has issued an update. On October 15, 2025, bioAffinity Technologies announced it has regained compliance with Nasdaq’s listing requirements, ensuring its common ...

The bottom line: No, you can’t make up for lost training time and you don’t even have to try. Instead, ease back into running ...

Investing.com -- Bioaffinity Technologies Inc (NASDAQ:BIAF) stock soared 79% in premarket trading Friday after the biotechnology company released three new case studies highlighting the effectiveness ...

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...

Data from the Phase Ib Beamion LUNG-1 trial evaluating HERNEXEOS® (zongertinib tablets) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant ...

High-profile mistakes have led to a loss in donor confidence. Experts say the system needs modernizing, not abandonment.